Blogs

Package integrity is a fundamental requirement for sterile pharmaceutical products. When a container closure system fails to maintain its integrity, the consequences range from contamination and potency loss to direct patient harm. FDA expects manufacturers to demonstrate that container closure systems perform as intended throughout the product's shelf life, and to have the data to prove it.

Container closure integrity testing (CCIT) is the primary tool used to establish and verify that assurance. When CCIT programs are absent, poorly validated, or reliant on methods that cannot produce defensible data, FDA inspections frequently result in observations and, in serious cases, warning letters. Understanding the patterns behind those citations helps manufacturers build programs that are both scientifically sound and inspection ready.

What Types of Packaging Integrity Failures Commonly Trigger FDA Observations?

FDA observations related to packaging integrity most often arise when manufacturers cannot demonstrate that their container closure systems reliably maintain sterility. The absence of scientifically sound CCIT, incomplete validation documentation, and inadequate investigation of known defects are recurring themes in inspection reports and warning letters.

Common FDA concerns include:

• Inadequate package integrity verification: No validated method in place to confirm container closure integrity before or after product release.
• Lack of scientifically sound test methods: Reliance on visual inspection or dye ingress testing without sensitivity justification or acceptance criteria.
• Insufficient validation documentation: Studies that lack repeatability data, challenge sample characterization, or defined worst-case conditions.
• Failure to demonstrate lifecycle integrity: No evidence that the packaging system maintains its performance across the full shelf life.
• Poor investigation of packaging defects: Defects identified during production not adequately investigated or documented.
• Inadequate risk assessments: No formal evaluation of packaging failure modes or their potential impact on product quality and patient safety.

Packaging Integrity Issue	Potential FDA Concern
Seal defects	Product contamination risk
Inadequate validation	Insufficient assurance of package integrity
Inconsistent testing	Lack of process control
Poor documentation	Data integrity concerns
Unverified packaging changes	Validation deficiencies

What Validation Deficiencies Are Frequently Observed During FDA Inspections?

Validation deficiencies are among the most commonly cited packaging-related issues in FDA inspections. Investigators examine whether manufacturers have adequately established that their chosen CCIT method is fit for purpose—and many programs fall short.

Frequently observed gaps include:

• Incomplete validation studies with no challenge samples or positive controls.
• Lack of sensitivity studies to demonstrate the method can detect relevant defect sizes.
• Failure to establish and justify acceptance criteria.
• Insufficient method repeatability and reproducibility data.
• Reliance on outdated testing approaches without scientific justification.
• No documented rationale for test method selection relative to the packaging system and product.

What Is CCIT Validation?

CCIT validation is the process of demonstrating that a container closure integrity test method is fit for its intended use and can reliably detect relevant package defects under defined operating conditions. A validated CCIT program establishes method performance characteristics such as sensitivity, repeatability, reproducibility, and acceptance criteria using appropriately characterized positive and negative control samples. It provides documented evidence that the method performs consistently and is suitable for evaluating container closure integrity throughout the product lifecycle.

Why Are Probabilistic Testing Methods Considered a Compliance Risk?

Probabilistic testing methods, including visual inspection, dye ingress, and microbial challenge testing, rely on subjective judgment or indirect indicators of package integrity. They produce pass/fail observations rather than quantitative measurements, and their results are highly dependent on operator skill, sample preparation, and environmental conditions.

This variability creates significant compliance exposure. When FDA investigators examine validation data for probabilistic methods, they frequently find limited sensitivity characterization, no defined acceptance criteria, and insufficient repeatability evidence. Deterministic testing methods eliminate these vulnerabilities by generating objective, numerical data that can be trended, validated, and defended in regulatory submissions.

Attribute	Probabilistic Methods	Deterministic Methods
Repeatability	Lower	Higher
Quantitative Data	Limited	Strong
Operator Dependency	High	Low
Sensitivity	Variable	Consistent
Regulatory Acceptance	Limited	Preferred

Why Does FDA Prefer Deterministic Testing Methods?

FDA and industry guidance documents, USP <1207> and PDA Technical Report No. 27, categorize deterministic methods as preferred for container closure integrity testing because they generate quantitative, reproducible data that can be scientifically validated. Unlike probabilistic methods, deterministic approaches do not depend on operator interpretation, making them more defensible during inspections and better suited to lifecycle validation programs.

How Does CCIT Vacuum Decay Improve Compliance and Validation Confidence?

Vacuum decay testing is a deterministic, non-destructive test method in which a sealed package is placed inside a test chamber, the chamber is evacuated to a defined vacuum level, and any pressure change over time is measured. A package with a leak path will show a measurable deviation from expected vacuum behavior, producing a quantitative result that is directly tied to the presence or absence of a defect.

From a compliance perspective, Vacuum Decay offers several advantages. Its results are objective and numerical, there is no operator interpretation involved. The method can be fully validated using characterized positive controls at defined defect sizes. It is non-destructive, enabling 100% inspection of production batches. And it is recognized in USP <1207.1> as a preferred deterministic method, providing a strong regulatory foundation for validation submissions and inspection responses.

Vacuum Decay is applicable to a wide range of pharmaceutical packaging formats, including vials, pre-filled syringes, ampoules, and flexible packaging, making it one of the most broadly deployed deterministic testing methods in sterile drug manufacturing.

How Does High Voltage Leak Detection (HVLD) Strengthen Container Closure Integrity Testing?

High Voltage Leak Detection (HVLD) applies a high-voltage electrical field across the external surface of a liquid-filled container. When a defect is present, the conductive liquid product creates a current pathway through the container wall, generating a detectable electrical signal. The method is non-destructive, does not require contact with the product, and produces quantitative results directly correlated to the presence of a breach.

HVLD is particularly effective for liquid-filled vials, cartridges, syringes, and ampoules, product types that are common in injectable sterile drug manufacturing. Its high sensitivity to both conductive and semi-conductive pathways gives it strong detection capability across a range of defect types and sizes.

For compliance purposes, HVLD offers the same core advantages as other deterministic testing methods: objective data, validated sensitivity, and operator-independent results. These characteristics directly address the validation deficiencies most commonly cited during FDA inspections of liquid-filled sterile product lines.

Technology	Test Method Type	Destructive / Non-Destructive	Key Application
Vacuum Decay	Deterministic	Non-destructive	Vials, syringes, flexible packaging
Airborne Ultrasound	Deterministic	Non-destructive	Flexible packaging
HVLD	Deterministic	Non-destructive	Liquid-filled containers

How Can Manufacturers Improve Inspection Readiness for Package Integrity Testing Programs?

Inspection readiness for package integrity testing is built through consistent process discipline, not last-minute preparation. Manufacturers that adopt deterministic testing methods, develop risk-based validation strategies, and maintain complete documentation are significantly better positioned when FDA investigators arrive.

Key best practices include:

• Adopting validated deterministic testing methods appropriate to the packaging format and product.
• Developing risk-based CCIT strategies that address packaging failure modes and their patient safety implications.
• Establishing comprehensive SOPs covering test method operation, acceptance criteria, and out-of-specification procedures.
• Maintaining complete and retrievable validation records, including protocols, reports, and raw data.
• Performing periodic reviews of CCIT performance data to identify trends and support continuous process verification.
• Documenting all personnel training and qualification for CCIT operations.
• Implementing data integrity controls that prevent unauthorized modification and support complete audit trails.

Inspection Readiness Checklist

• Risk-based CCIT strategy established
• Validation protocols documented
• Acceptance criteria justified
• Repeatability studies completed
• Data integrity controls implemented
• Change management procedures maintained
• Personnel training documented
• Periodic reviews conducted

What Are the Key Takeaways for Avoiding Packaging Integrity-Related FDA Observations?

FDA observations related to packaging integrity share a common profile: validation programs that cannot withstand scientific scrutiny, documentation that is incomplete or inaccessible, and testing methods that produce data of limited defensibility. Addressing these vulnerabilities requires deliberate investment in the right technologies and quality infrastructure.

The most important actions manufacturers can take are:

• Replace probabilistic methods with validated deterministic testing methods that generate quantitative, reproducible data.
• Validate thoroughly: Sensitivity studies, repeatability data, and justified acceptance criteria are non-negotiable for inspection readiness.
• Document everything: From instrument qualification to personnel training, the paper trail is the compliance record.
• Apply a lifecycle approach: CCIT is not a one-time qualification. Ongoing monitoring and change control are expected.
• Understand your packaging risk: A formal risk assessment guides technology selection and validation scope.

Conclusion

FDA warning letters related to packaging integrity are preventable. The underlying causes like inadequate validation, reliance on probabilistic methods, and incomplete documentation, are well understood, and the industry has the tools to address them. Deterministic testing methods such as Vacuum Decay, Airborne Ultrasound, and HVLD provide the scientific foundation that modern CCIT programs require. Manufacturers that invest in rigorous validation programs, maintain complete records, and align their CCIT strategies with current regulatory expectations will find that inspection readiness is not a separate exercise, it is simply the output of a well-run quality system.

Contamination control in sterile pharmaceutical manufacturing has never faced more rigorous scrutiny. As biologics and complex parenterals expand the drug product landscape, packaging integrity has moved from a supporting quality check to a central element of patient safety strategy. A single undetected defect, a microleak or a failed seal can compromise product sterility in ways no visual inspection will catch.

Container closure integrity testing (CCIT) sits at the heart of this challenge. The revised EU GMP Annex 1, which took full effect in August 2023, formalizes what the industry has been trending toward for years: a science-based, data-driven approach to sterile packaging quality control that demands more than legacy probabilistic methods can deliver.

What Annex 1 Actually Requires for Packaging Systems?

The revised annex is explicit: container closure integrity must be demonstrated and maintained throughout shelf life, and the methods used to verify it must be scientifically justified. Key requirements include:

• Contamination Control Strategy (CCS): Manufacturers must document a holistic, risk-based CCS that identifies and controls potential contamination pathways, including risks associated with container closure and packaging integrity.
• Lifecycle validation: Package integrity testing is not a one-time qualification. Annex 1 expects ongoing verification from development through commercial manufacturing.
• Data integrity: Electronic records must follow ALCOA+ principles—attributable, legible, contemporaneous, original, and accurate—with complete audit trails.
• Continuous process verification: Production-scale CCIT programs, not just method development studies, are expected as evidence of sustained integrity control.

Packaging Risk and Patient Safety

The clinical stakes make the regulatory emphasis straightforward. Packaging defects create direct pathways for microbial ingress, oxidative degradation, and sterility loss, none of which is detectable by visual inspection alone.

Packaging Risk	Potential Impact
Microleaks	Sterility loss; microbial ingress
Seal defects	Product contamination; potency reduction
Closure defects	Reduced shelf life; failed stability
Packaging damage	Product recalls; regulatory action

The Shift to Deterministic Test Methods

Annex 1 does not name a specific CCIT technology. What it does require is quantitative data, science-based validation, robust audit trails, and lifecycle monitoring, which is difficult to satisfy with probabilistic methods. Dye ingress and bubble emission testing produce subjective, binary results with limited sensitivity and no defensible data trail.

Deterministic test methods address each of those gaps directly. They generate objective, numerical outputs that can be trended, archived, and retrieved during regulatory inspections. USP <1207> and PDA Technical Report No. 27 (Revised) both categorize deterministic methods as preferred for their objectivity and sensitivity. In practice, regulators conducting Annex 1 inspections increasingly expect manufacturers to justify any reliance on probabilistic alternatives.

1. Vacuum Decay: Vacuum decay testing places a sealed package in a test chamber, draws the chamber to a defined vacuum level, and measures pressure change over time. A leak path produces a measurable differential. The method is non-destructive, requires no reagents, and is well suited for 100% in-line testing of vials, syringes, ampoules, and flexible packaging. It is recognized in USP <1207.1> and widely accepted across regulatory jurisdictions.

2. High Voltage Leak Detection (HVLD): HVLD applies a high-voltage electrical field across a liquid-filled container. A defect allows the conductive product to complete a circuit through the container wall, producing a detectable signal. The method is non-destructive and particularly effective for aqueous injectables. It integrates readily into production-scale quality control programs, directly supporting Annex 1's expectation for ongoing monitoring.

3. Helium Leak Detection: Helium Leak detectionuses helium as a tracer gas, measured by mass spectrometry, to detect leak paths at very high sensitivity—down to 10?? mbar·L/s. It is most commonly applied during package development, qualification studies, and validation to establish acceptance thresholds and characterize novel packaging configurations.

Technology	Test Type	Sensitivity	Destructive?	Typical Use
Vacuum Decay	Deterministic	High	No	Vials, syringes, flexible packaging
HVLD	Deterministic	High	No	Liquid-filled containers; injectables
Helium Leak Detection	Deterministic	Very High	Typically, yes	Validation and package development

Conclusion 

EU GMP Annex 1 has made sterile packaging quality control a primary contamination prevention discipline, not a final release checkpoint. Its requirements for science-based validation, lifecycle monitoring, and complete data traceability set a clear direction: deterministic test methods, robust CCIT platforms, and quality systems built to withstand inspection. Manufacturers that align their packaging validation programs with these expectations now will be better positioned as global regulatory standards continue to converge around the same principles.

Frequently Asked Questions

1. Does Annex 1 require deterministic CCIT methods?

Not by name. However, its requirements for quantitative data, science-based validation, and complete audit trails are difficult to meet with probabilistic methods. Regulators increasingly expect manufacturers to justify reliance on dye ingress or bubble emission testing, especially for high-risk products.

2. What is a Contamination Control Strategy under Annex 1?

A CCS is a documented, risk-based plan covering all potential contamination pathways in sterile manufacturing—including packaging defects. It must be maintained throughout the product lifecycle and reviewed when processes or packaging systems change.

3. What CCIT technologies are accepted for Annex 1 compliance?

Vacuum Decay, HVLD, and Helium Leak Detection are the most widely accepted deterministic technologies for pharmaceutical packaging. Selection should be based on a formal risk assessment that accounts for container type, fill, and sensitivity requirements.

4. When does CCIT validation need to be performed?

Annex 1 takes a lifecycle approach. Validation is required at package development and qualification, at commercial launch, and whenever a packaging system, material, or process undergoes a significant change. Ongoing process verification during commercial manufacturing is also expected.

5. Does Annex 1 apply outside the EU?

Annex 1 applies to any manufacturer supplying sterile products to European markets. Its principles also increasingly inform FDA, WHO, and ICH expectations, making compliance broadly relevant for global sterile drug manufacturers.

A batch of sterile injectables cleared your QC line on a Tuesday morning. By Thursday, a single compromised vial had failed container closure, and the contamination was traced back to a pinhole defect smaller than 20 microns. The package looked perfect. The seal appeared intact. Your dye ingress test gave you a clean result. That scenario plays out more often than the industry likes to admit, and it costs manufacturers in recalls, regulatory actions, and far worse: patient safety events.

The question isn't whether package integrity failures happen. They do. The real question is whether your testing method catches them before they leave your facility, and whether it can do so without destroying the sample in the process.

That's where Vacuum decay testing standardized under ASTM F2338, has earned its place as one of the most reliable container closure integrity testing (CCIT) methods available today. And unlike many other techniques, it works with equal precision on dry-product packages and liquid-filled packages, without modification, without solvents, and without sacrifice of the sample.

What does ASTM F2338 Measure?

At its core, vacuum decay is a pressure-based leak detection method. The test places a package inside a sealed, evacuated test chamber. The chamber is brought to a defined vacuum level, typically in the range of 1 to 5 mbar absolute. Once that vacuum is established and stabilized, the instrument monitors the chamber pressure for a defined dwell time, usually between 5 and 30 seconds.

If the package is intact, the chamber pressure holds steady. If there's a breach, a microhole, a compromised seal, a crack in a rigid container, gas or vapor escapes from the package into the chamber. That escape registers as a measurable pressure rise. The magnitude and rate of that pressure rise directly correlate to leak size and location.

Key principle: ASTM F2338 does not rely on detecting liquid, dye, or tracer gas. It detects pressure change — a universal physical phenomenon that occurs regardless of what is inside the package.

Dry Filled Packages vs. Liquid Filled Packages: A Side-by-side Comparison

Parameter	Dry-filled packages	Liquid-filled packages	Common ground
Detection mechanism	Gas flow (viscous and molecular)	Vapor / dissolved gas escape at reduced pressure	Pressure rise in evacuated chamber
Primary physics	Knudsen / Poiseuille flow	Henry's Law, vapor pressure, degassing	Pressure differential across defect
Vacuum depth	Lower vacuum often sufficient	Requires careful optimization to avoid false signals	Defined per ASTM F2338 validation
Key risk in method dev	Headspace composition variability	Over-evacuation causing false positives	Requires positive and negative controls
Typical sensitivity	2–10 micron defects	5–20 micron defects (liquid-dependent)	Deterministic, quantitative output
Best application	Blisters, sachets, lyo vials, pouches	Parenterals, prefilled syringes, ampoules	Any hermetically sealed primary container

Advantages that matter on the plant floor

• Non-destructive by design. The package is not opened, punctured, submerged, or exposed to reagents. It can be returned to the batch after testing, which is critical for high-value biologics and small-volume parenterals where destructive testing means discarding saleable product.
• Quantitative, not interpretive. Unlike dye ingress or bubble emission, vacuum decay gives a numerical pressure-rise value. Pass/fail decisions are based on thresholds, not technician judgment. That's important for audit trails and regulatory submissions.
• Rapid cycle times. Most tests complete in 30–90 seconds per unit. High-throughput configurations can test multiple packages simultaneously, making 100% testing, rather than AQL sampling, a realistic option for critical products.
• Repeatable and reproducible. Because the method is instrument-driven, inter-operator and inter-laboratory variability is significantly lower than visual or dye-based methods. This supports validation under ICH Q2(R1) requirements.
• No consumables or hazardous materials. Unlike Helium Leak detection, there's no tracer gas required. Unlike dye ingress, there's no methylene blue or other colorant. Operational costs are low and disposal considerations are minimal.
• Works across container types and sizes. From 0.5 mL lyophilized vials to 500 mL IV bags, instrument manufacturers offer chamber configurations that accommodate a wide range of primary containers. One method, multiple formats.

How Vacuum Decay Fits within Broader CCIT Strategy?

In the context of CCI technologies, vacuum decay occupies the middle ground between probabilistic methods (dye ingress, bubble emission) and high-sensitivity tracer methods (helium mass spectrometry, headspace analysis). It offers better sensitivity than dye ingress and far lower equipment and operational costs than helium-based systems.

For many manufacturers, vacuum decay becomes the primary release test method, with headspace analysis or helium leak testing reserved for development-stage defect characterization. This tiered approach, endorsed in USP <1207>, allows facilities to optimize both sensitivity and throughput at each stage of the product lifecycle.

Regulatory agencies, including the FDA and EMA, have increasingly emphasized deterministic CCI methods over probabilistic ones, particularly for sterile products. Vacuum decay, validated per ASTM F2338, qualifies as a deterministic method — a distinction that carries weight in both NDA submissions and inspection responses.

Frequently Asked Questions

1. What defect sizes can vacuum decay detect in liquid-filled vials?

For aqueous liquid-filled vials, validated vacuum decay methods typically achieve detection of defects in the 5–20 micron range, depending on the liquid formulation, headspace volume, and test parameters. Viscous or high-density formulations may reduce sensitivity slightly. Specific detection limits must be established during method validation using calibrated positive-control samples with known defect sizes.

2. Is vacuum decay per ASTM F2338 accepted by the FDA for container closure integrity testing?

Yes. The FDA recognizes ASTM F2338 as a validated standard for vacuum decay leak testing. The method is classified as a deterministic CCIT technique under FDA's 2008 guidance on container closure systems and aligns with the framework described in USP <1207>. Manufacturers are expected to validate the method for their specific container-closure system and product type.

3. Can vacuum decay be used for 100% inspection rather than sampling?

Yes, and this is one of its key operational advantages. With cycle times of 30–90 seconds per unit and multi-chamber instrument configurations, 100% inline or at-line testing is achievable for many production formats. This eliminates the statistical uncertainty of AQL-based sampling, which is particularly valuable for sterile injectables and other high-risk product categories.

4. How does vacuum decay compare to dye ingress testing for regulatory purposes?

Dye ingress is classified as a probabilistic method — its reliability depends on operator technique, dye concentration, immersion time, and visual inspection variability. Regulatory guidance increasingly favors deterministic methods like vacuum decay for product release testing, particularly in the sterile injectable space. Dye ingress may still be useful as a development tool or for method comparison during validation, but it is not recommended as a standalone release test for parenteral products.

5. What validation studies are required to qualify a vacuum decay method under ASTM F2338?

A complete validation package typically includes: instrument qualification (IQ/OQ/PQ), method development studies to optimize test parameters (vacuum level, stabilization time, test time), sensitivity determination using positive-control samples with calibrated defects, specificity studies to confirm the method does not generate false positives from normal package variation, and reproducibility and repeatability studies across operators, days, and instruments. Reference standards from PTI, Lighthouse Instruments, or equivalent suppliers provide calibrated leak standards for this purpose.

Pharmaceutical packaging has grown considerably more complex over the past two decades. Prefilled syringes, blow-fill-seal (BFS) containers, cartridges for autoinjectors, and highly concentrated biologic formulations have all become standard parts of the product landscape. What many of these formats share is minimal internal headspace, and that matters more than most people outside the CCIT world appreciate.

Headspace is not just an incidental feature of container design. For most pressure-based and gas-based leak detection technologies, it is the measurement medium. When headspace volume drops, so does the detectable signal that a leak generates. The result is a narrower, noisier measurement window that demands both better equipment and more rigorous method development.

Container closure integrity testing (CCIT) for low-headspace products is not simply a matter of applying a standard method and tightening the acceptance criteria. It requires a fundamentally different approach to test configuration, sensitivity optimization, and validation strategy. Getting it wrong has real consequences, from compromised sterile products reaching patients to expensive false rejects disrupting manufacturing.

What are the Pharmaceutical Formats Commonly Affected by Low Headspace?

Pharmaceutical formats commonly affected by low headspace include:

• Prefilled syringes: Typically filled near nominal volume with minimal residual gas space.
• BFS (Blow-Fill-Seal) containers: Often sealed with near-zero headspace depending on fill design.
• Cartridges for autoinjectors and pen injectors: Compact formats with tightly controlled fill volumes.
• Small-volume vials (1–2 mL): Limited internal volume by design.
• Biologic and cell therapy packaging: Often filled under modified atmosphere with controlled, minimal headspace.
• Ophthalmic unit-dose containers: Single-use BFS or thermoform formats with near-complete fill.

The role of headspace in leak detection is straightforward but easily underestimated. When a defect is present, gas either enters or escapes the container through the leak pathway. The pressure change or tracer gas signal that results is proportional to the internal volume available to participate in that exchange. Less headspace means a smaller, faster-attenuating signal.

What are the Risks of Inaccurate Leak Detection in Low-Headspace Containers?

When a CCIT method is not well-suited to a low-headspace product, the consequences span both directions of the quality spectrum. Neither outcome is acceptable in sterile pharmaceutical manufacturing.

False Accepts: The Invisible Risk

• Compromised containers pass testing and enter the supply chain.
• Microbial ingress through sub-visible defects can compromise sterility without visible product change.
• Oxygen or moisture entry can degrade potency in biologics, lyophilized drugs, and oxygen-sensitive formulations.
• Shelf life is shortened, potentially causing out-of-specification results at stability timepoints.
• Patient safety risk if sterile barrier failure goes undetected.

False Rejects: The Operational Risk

• Intact, conforming containers are incorrectly rejected, increasing manufacturing loss.
• High false reject rates can mask real quality trends by creating background noise in the data.
• Investigation burden increases as QA attempts to explain non-reproducible failures.
• Distorts process capability data and complicates ongoing validation maintenance.

What are the Strategies for Testing Low-Headspace Products?

1. Helium Leak Detection

Helium Leak detection works by filling or purging the container headspace with helium, then placing the package in a vacuum chamber or scanning it with a mass spectrometer sniffer probe. The instrument detects individual helium atoms escaping through any defect. Because the signal is based on tracer gas concentration rather than bulk pressure differential, it is far less dependent on available headspace volume.

Key advantages for low-headspace applications:

• Sensitivity independent of headspace volume in tracer gas mode.
• Detection capability down to 10?¹² mbar·L/s under optimized conditions.
• Fully deterministic and quantitative, produces an actual leak rate value.
• Directly correlatable to MALL for validation under USP <1207>.
• Well-suited to rigid formats: vials, cartridges, ampoules, and prefilled syringes.
• Atmospheric helium background is extremely low, providing an inherently high signal-to-noise environment.

2. Vacuum Decay Technology

Vacuum decay is a non-destructive, deterministic method that requires no tracer gas or sample preparation. The container is tested in exactly the condition it would be distributed. For standard-headspace products, it is one of the most widely used CCI technologies in pharmaceutical manufacturing.

For low-headspace containers, vacuum decay remains effective when properly optimized:

• Chamber geometry: a tightly fitting test chamber minimizes dead volume, concentrating the signal from any leak.
• Vacuum level selection: optimized to maximize differential between headspace pressure and chamber pressure.
• Extended stabilization and measurement intervals: allow weak signals to accumulate above the noise floor.
• High-resolution pressure transducers: necessary to detect small pressure changes in low-headspace conditions.
• Temperature-controlled test environments: reduce thermal artifact pressure signals that can obscure real leak data.

Helium Leak Detection vs. Vacuum Decay: Technology Comparison for Low-Headspace Products

Criterion	Helium Leak Detection	Vacuum Decay
Operating principle	Tracer gas (He atoms) detected by mass spectrometry	Pressure rise measurement in evacuated test chamber
Sensitivity	Extremely high: ~10?¹² mbar·L/s	High: low single-digit micron range when optimized
Headspace volume dependency	Low — tracer gas detection independent of bulk pressure	Moderate — signal is amplified by chamber geometry optimization
Quantitative output?	Yes — leak rate in mbar·L/s	Yes — pressure differential data correlatable to leak size
Deterministic?	Yes	Yes
USP <1207> recognized?	Yes	Yes
Best-fit formats	Rigid containers: vials, cartridges, ampoules, PFS	Broad: vials, bottles, blisters, pouches, PFS, BFS
Key low-headspace advantage	Signal not limited by headspace volume in tracer mode	Chamber geometry optimization compensates for low signal
Primary limitation	Requires headspace modification; not always releasable post-test	Parameter development required for very low headspace

Why Does Deterministic CCIT Matter for Modern Pharmaceutical Packaging?

The regulatory direction set by USP <1207> is clear: deterministic CCIT methods are the preferred approach for package integrity testing of sterile pharmaceutical products, particularly where risk is high. Probabilistic methods, including dye ingress, bubble emission, and microbial challenge tests used in isolation, remain in some protocols. Still, their inability to reliably detect sub-10-micron defects or generate quantitative data makes them increasingly difficult to justify for high-risk products.

Low-headspace products make this case even more sharply. A dye ingress test applied to a prefilled syringe with 0.3 mL of headspace does not generate defensible leak rate data. It tells you whether dye crossed a barrier under specific immersion conditions. It does not tell you whether a 5-micron defect was present, what the headspace exchange rate was, or whether the package meets its MALL.

FDA inspectors reviewing CCIT programs for parenteral and biologic products increasingly expect manufacturers to justify their chosen method against the product's MALL. For any product where the MALL falls below 10 μm, that justification needs to be rooted in deterministic data. Low-headspace products are not an exception to that expectation, if anything, they make meeting it harder, which is exactly why method selection and optimization matter from the earliest stages of packaging development.

Frequently Asked Questions

1. What is headspace in pharmaceutical packaging?

Headspace is the gas-filled volume inside a sealed pharmaceutical container that is not occupied by the drug product. It consists of air, nitrogen, or a controlled inert atmosphere depending on formulation requirements. In leak detection, headspace volume directly determines the magnitude of the pressure or gas signal generated by a defect.

2. Why does low headspace make leak detection more difficult?

Low headspace reduces the internal gas volume available for pressure exchange when a defect is present. This produces a smaller, faster-decaying signal that is harder to distinguish from background measurement noise. It increases signal-to-noise challenges, validation complexity, and the risk of false accepts or false rejects if the test method is not properly optimized.

3. What is signal-to-noise ratio in CCIT and why does it matter?

Signal-to-noise ratio (SNR) in CCIT describes the relationship between the measurable pressure or tracer gas signal produced by a defect and the background variation inherent in the measurement system. A low SNR, typical in low-headspace testing, makes it harder to reliably distinguish real leaks from system noise, increasing the risk of testing errors.

4. Which CCIT technologies are best suited for low-headspace pharmaceutical containers?

Helium leak detection and vacuum decay are the two deterministic CCIT methods with demonstrated capability for low-headspace products. Helium detection is largely independent of headspace volume in tracer gas mode. Vacuum decay, when properly optimized with close-fitting chamber geometry and high-resolution pressure transducers, is effective across a wide range of headspace volumes.

5. What does USP <1207> require for CCIT in sterile pharmaceutical packaging?

USP <1207> requires that container closure integrity testing methods demonstrate sensitivity at or below the product-specific Maximum Allowable Leakage Limit (MALL). It distinguishes deterministic methods — which produce quantitative, measurable data — from probabilistic methods, and supports deterministic testing as the preferred approach for high-risk sterile products.

Maintaining the container closure integrity of vials stands as a paramount concern within pharmaceutical manufacturing, crucial for upholding product quality, efficacy, and ensuring patient safety. Conventional vial leak testing methodologies possess inherent limitations in detecting microleaks, posing a potential risk to product sterility. In response to this challenge, the advent of MicroCurrent High Voltage Leak Detection (HVLD) technology presents a groundbreaking solution, boasting unparalleled sensitivity and precision in vial leak detection.

Overview of Vial Leak Testing

Vial leak testing constitutes a pivotal stage in pharmaceutical manufacturing, serving to pinpoint any potential breaches in vial integrity that could culminate in contamination or compromise product stability. Established techniques encompass visual inspection, dye ingress and other destructive methods. Nonetheless, these methods may fall short in identifying microleaks, characterized by minute defects capable of facilitating the ingress of contaminants. Hence, manufactures are now moving towards more deterministic technology that offer quantitative and reliable test results.

Vial Leak Testing using MicroCurrent HVLD Technology

MicroCurrent HVLD is a non-destructive method for assessing the integrity of container closures in non-porous pharmaceutical and parenteral products. This technique relies on the principle of electrical current to detect any leaks in a range of liquid-filled products, including those with extremely low conductivity such as sterile water for injection (WFI) and products containing proteins or suspensions.

Compared to conventional HVLD technology, MicroCurrent HVLD significantly reduces product voltage exposure to less than 5%, thereby eliminating any potential risk to the product and reducing Ozone formation during testing.

In this method, the container is scanned using high voltage probes. One side of the container is subjected to high voltage, while a ground probe is attached to the other side. If the container is intact, both sides offer complete electrical resistance, and no significant current passes through. However, if a micro-leak or fracture is present, breakdown resistance occurs, allowing current to flow through the defect.

HVLD is unique among leak detection methods as it does not require mass to pass through the defect site; instead, it transmits electricity through the crack. This sensitivity enables HVLD to detect leaks that other conventional leak test solutions may miss.

Benefits of MicroCurrent HVLD Technology

• Scalable from the R&D Laboratory to production line
• Non-destructive, non-invasive, no sample preparation
• High level of repeatability and accuracy
• Effective across all parenteral products, including extremely low conductivity liquids (WFI)
• Lower voltage exposure produces no ozone, eliminating risk to the product and environment
• Listed in USP Chapter <1207> as recommended method for parenteral liquid package integrity testing
• Robust method and approximate 3x Signal-Noise-Ratio for a wide range of product classes and package formats
• Simplifies the inspection and validation process

The ability to evaluate the possibility of the container closure system to maintain a sterile barrier or to prevent leakage is a vital step in determining the safety and suitability of primary packaging. The United States Pharmacopeia (USP) and Food and Drug Administration (FDA) implement strict guidelines for container closure integrity testing (CCIT) as the driving factors behind safety examination of materials and closure systems in the US.

Historically, the two most common procedures for testing container closure integrity were dye immersion and microbial immersion (both probabilistic tests). In 2016, USP provided recommendations stating that deterministic methods are favored over probabilistic methods for CCIT because they produce reliable and predictable findings at low detection limits.

Non-Destructive CCI Test Methods Offered by PTI

1. Vacuum Decay Technology

Vacuum Decay has been substantiated as one of the most practical and sensitive vacuum-based leak detection methods. This test provides a quantitative result that is reliable, reproducible, and accurate, as well as a pass or fail judgement. PTI's VeriPac equipment was used to produce the ASTM F2338 standard vacuum decay test procedure. It is also recognized in the United States Pharmacopeia Chapter on CCI and is classified in ISO 11607. Using an absolute pressure or differential pressure transducer leak test device, VeriPac's non-destructive technology can detect package leaks and unseen defects.

2. Volumetric Imaging Technology

The OptiPac One-Touch Tool-less technology is intended for non-destructive leak detection in blister packages. To identify leaks, the OptiPac employs volumetric imaging technology to measure the motion of a blister package under vacuum. With new blister package formats, the interface is practical and straightforward to set up, requiring no tooling changeover or extensive parameter modifications as seen with previous non-destructive blister package inspection systems. The system collects volumetric data from each cavity, responding to variable cavity shapes, sizes, and configurations of various blister pack forms.

2. MicroCurrent HVLD Technology

PTI packaging and inspection systems transformed the traditional HVLD method and offered a game-changing new technology for assessing the integrity of all parenteral and biological products, including low conductivity liquids such as sterile water for injection (WFI). When compared to standard HVLD solutions, this innovative technology known as MicroCurrent HVLD uses approximately 50% less voltage and exposes the product and environment to less than 5% of the voltage. The Microcurrent HVLD test method may detect and locate pinholes, micro-cracks, stopper/plunger leaks, non-visible leaks under crimping, and a variety of other faults.

PTI provides package leak testing, seal integrity testing, and container closure integrity testing systems (CCIT). Our technologies eliminate subjectivity from package testing and employ ASTM-compliant test methodologies. The inspection technologies developed by PTI are deterministic test procedures that generate quantitative test result data.

As technological advancements lead to an ever-increasing world of routes of administration for new and existing drugs, packaging decisions for such options have become more challenging. There are multiple options for drug delivery container formats, and each should be continuously reviewed with reference to compliance and accuracy of delivery. Packaging is a critical point of concern whenever a new drug product is introduced into the market. When it comes to parenterals, there has been a dramatic increase in these packaging formats over the past 10 years. Apart from typical formats of vial and syringes, dual-chamber devices, cartridges and electronically enabled devices have been introduced, all which demand high levels of packaging accuracy. So how do we ensure the ability of the packages to maintain sterility of the drug? Quality assurance with the proper Container Closure Integrity Test (CCIT) method is critical.

CCI Testing using E-Scan 655 MicroCurrent HVLD

The E-Scan 655 technology utilizes the MicroCurrent conductivity test method to non-destructive evaluate container closure integrity. MicroCurrent technology exposes the package and product to lower voltage than other conductivity based solutions. This unique technology requires no sample preparation and is a non-contact and non-invasive test method. What makes E-Scan 655 technology unique is its ability to test a wide range of liquid-based products including low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. The system also features a fast test cycle and is simple to operate. Additional benefits include quick product changeover and an easy recipe set up to accommodate a wide range of products and applications. The offline E-Scan 655 method can be migrated from the laboratory to automated 100% inline testing applications at high production speeds.

Testing Procedure

Using a set of electrode probes, E-Scan system tests a non-conductive container that is sealed. The container material can vary from glass, plastic, or poly laminate. The container or package must contain liquid (minimum fill 30%). In case of any defect including pinhole or crack, there will be a resistance differential and change in current flow indicating a breach in the container. The approximate defect location can be identified.

Benefits of MicroCurrent HVLD technology:

• Non-destructive, non-invasive, no sample preparation
• High level of repeatability and accuracy
• Effective across all parenteral products, including extremely low conductivity liquids (WFI)
• Lower voltage exposure produces no ozone, eliminating risk to the product and environment
• Listed in USP Chapter <1207> as recommended method for parenteral liquid package integrity testing
• Robust method and approximate 3x Signal-Noise-Ratio for a wide range of product classes and package formats
• Simplifies the inspection and validation process

Packaging is an essential part of the pharmaceutical industry, given the sensitive nature of the contents. High-risk medications and lifesaving drugs need utmost care and protection until they reach the patient. As such, stringent industry standards apply to pharmaceutical packaging. Manufacturers give high priority to safety and quality while selecting packaging materials for a drug or healthcare product. The packaging should be able to act as a barrier against external contamination and chemical reactions. Exposure to reactive gases can alter the physical, chemical and biological attributes of the products. This makes Container Closure Integrity Testing of pharmaceutical packaging a regulatory requirement.

Role of MicroCurrent HVLD in ensuring pharmaceutical package integrity

Often referred to as the conductivity and capacitance test, High Voltage Leak Detection (HVLD) is a test method found to be highly effective in detecting the presence and location of leaks in a wide range of pharmaceutical and parenteral applications. It can be used for leak testing in nonporous, rigid or flexible packages, as well as packages containing liquid or semi-liquid products. High Voltage Leak Detection test is conducted using electrical conductivity and resistance principle. This method operates by passing high voltage micro current signals through sample packages. Under the presence of a leak, the electrical resistance of the sample declines, causing an increase in current. Compared to other leak detection methods that rely on flow of gas or liquid, HVLD technology relies on “flow” of current. This reduces challenges with defect clogging compared to flow-based analysis.

The latest evolution of HVLD, PTI’s patent pending MicroCurrent technology, aims to achieve a high level of CCI assurance across the entire range of pharmaceutical products. The MicroCurrent HVLD reduces voltage exposure to the product to less than 5% of the voltage exposure experienced when testing with comparable HVLD solutions. Reducing exposure voltage not only reduces any risk that the voltage poses to the product, but also greatly reduces the production of Ozone during operation when compared with traditional HVLD solutions. Ozone in the headspace of a container can be detrimental to the product, and in the operating environment can affect respiratory health.

Benefits:

Non-destructive Container Closure Integrity Test (CCIT)

Requires no sample preparation

Capability to test multiple packages in a single test cycle

Identifies which package is defective

Simplifies the inspection and validation process

Supports sustainable packaging initiatives

ASTM test method and FDA standard

Cost effective with rapid return on investment

Parenteral product package systems are expected to provide barriers against drug contamination and ensure stability and sterility throughout the entire shelf life. Any defect in packaging can cause microbial contamination, exposure to gases and water vapor, resulting in product deterioration. Furthermore, the industry has seen a spike in demand for combination products and patient-centered drug delivery systems, that present a high level of technical risk for maintaining container closure integrity (CCI). Therefore, container closure integrity testing is an important stage in the sterile drug product lifecycle.

Automated package inspection with VeriPac LPX

As the pharmaceutical industry continues to grow, manufacturers require capable, consistent automated solutions for container closure integrity testing. Automated inspection systems improve package reliability, reduce chances of product recalls and packaging failure.

PTI's VeriPac LPX series are a line of fully automated package quality inspection systems for 100% inline testing. The LPX enables enhanced automated testing that provides a high level of confidence in packaging line performance. Veripac LPX is a practical and reliable solution for the problems associated with performing infrequent testing as well as for recognizing and correcting process-related quality issues.

Sensitivity and reliability go hand in hand with CCI testing. The VeriPac LPX 430.8S is the next generation automated inspection system for container closure integrity testing of parenteral products. Automated for 100% testing or batch release, the VeriPac PLX 430.8S is an eight-station dual chamber design, with robotic testing platform for pre-filled syringes and vials, products filled with lyophilized product, small molecule liquids and Water for Injection (WFI).

The VeriPac LPX features a dynamic robotic design, tailored to fit varied production requirements. LPX Series are scalable, modular solutions to meet production line demands. This adaptable platform provides reliable automated handling of a variety of packaging formats. Applications for LPX automation range from flexible packaging to rigid containers, and parenteral products. Additionally, VeriPac LPX allows easy changeover for testing different size packages on the same system.

Benefits of VeriPac LPX test systems

• Automated testing enables the highest level of container quality assurance
• Self-teach software
• Non-drift transducers for consistent leak detection
• Low false rejects
• Operator friendly
• Reject statistics & test result trends
• 24/7 operation
• Increased productivity
• Reduced downtime
• Low maintenance

Container closure integrity may be understood as the ability of container closure systems to maintain a sterile barrier against possible contaminants that can deteriorate the quality of the final product. Even a microscopic leak or breach of the sterile barrier can cause external contaminants to enter the product and compromise its healing properties. Parenteral products are at the highest risk of all package formats. Vials, ampoules and prefilled syringes have the highest potential for microbial growth, and the risk to the end patient amplifies the focus needed on CCI for these applications. Although dye ingress and microbial ingress are common leak testing methods, they are proven to provide subjective results that lack accuracy. Hence regulatory bodies have instructed a shift towards more deterministic test methodologies that can be controlled, calibrated and provide a definitive determination of CCI.

High Voltage Leak Detection (HVLD) is an effective Container closure integrity technique for non-destructive package inspection of non-porous pharmaceutical and parenteral products. This technology operates on the simple property of electrical current. The latest evolution of HVLD, PTI’s patented MicroCurrent HVLD technology , aims to achieve a high level of CCI assurance across the entire range of parenteral products. It can precisely detect any leak in a wide range of liquid- filled products including extremely low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. The MicroCurrent HVLD reduces voltage exposure to the product to less than 5% of the voltage exposure experienced when testing with comparable HVLD solutions. Reducing exposure voltage not only reduces any risk that the voltage poses to the product, but also greatly reduces the production of Ozone during operation when compared with traditional HVLD solutions.

How does MicroCurrent HVLD technology work?

Under this method, the container is scanned by the high voltage probes. High voltage is applied to one side of the container and a ground probe on the opposing side. If the package has no leak, the two container walls (high voltage side and ground side) provide full electrical resistance and no significant current is measured passing through the vial. If there is a micro-leak or crack in one of the container walls, the break-down resistance is reached and the current passes through. HVLD is the only leak detection technology that does not require mass to pass through a defect site, requiring only the passage of electricity through a crack. This characteristic makes HVLD sensitive to leaks in which most leak test solutions cannot identify. Applications of High Voltage Leak Detection Technology include testing of the following package formats:

• Pre-filled syringes
• Ampoules
• Drug product cartridges
• Liquid filled vials

Benefits of MicroCurrent HVLD:

• Deterministic, non-destructive, non-invasive
• High level of repeatability and accuracy
• Ideal package integrity solution for parenteral products
• Low voltage exposure to the product and environment
• Offline and 100% online inspection at high production speeds
• Referenced in USP 1207 guideline

The pharmaceutical industry is crucial to the health care system as they assure treatments that were unimaginable a few years ago. As the industry grows in importance, the techniques of primary packaging for pharmaceutical products, especially high-risk medicines have taken on new prominence.

Since many high-risk pharmaceutical products are filled and sealed in combination devices, it’s critical for manufacturers to ensure that the components function well together. Hence, design and distribution considerations are critical to both the drug and the container. Manufacturing inconsistencies and tolerance differences in packages containing multiple components are primary contributors to distribution issues. Often, such inconsistencies result in container closure failure, causing serious implications down the supply chain. For instance, glass vials and pre-filled syringes may not seal properly at critical fill-finish closure points. Such a failure can cause oxygen or other environmental contaminants to enter the product and compromise the efficacy of the drug in the barrel. At this point, it is critical to use the most precise leak testing method possible.

Why Container Closure Integrity testing is important?

As per the FDA- Food and Drug Administration, A container and closure system refers to "the entirety of packaging components that together contain and protect the product". In simple words, Container Closure Integrity testing can be understood as a leak detection test. CCI solutions include non-destructive package inspection technologies to ensure product sterility throughout the product’s lifecycle. CCIT plays a vital role in ensuring that the products are free from any possible contamination. Conventionally, probabilistic test methods like bubble tests, dye ingress and microbial challenge were extensively used in pharmaceutical package testing. Since it was found that such test results lacked accuracy and reliability, the United States Pharmacopeia (USP) released guidance in 2016 stating that deterministic methods are preferred over probabilistic test methods. With this new USP <1207> chapter guidance, manufacturers today rely on non-destructive alternatives like Vacuum Decay technology and Micro Current HVLD technology that ensure highly sensitive package integrity solutions.

1. Vacuum Decay technology: Vacuum Decay technology is a non-destructive container closure integrity solution capable of detecting leaks in nonporous, rigid or flexible packages. Vacuum Decay leak testing is conducted by placing a sample package in a well-fitting evacuation chamber, which is provided with an external vacuum source. The vacuum levels as well as the change in vacuum over a fixed test time are closely observed using single or dual vacuum transducer technology. Changes in vacuum level beyond a predetermined pass/fail limit indicate defects within the package. VeriPac Vacuum Decay series can non-destructively test packaging down to sub-micron leak rates - making it an excellent alternative to destructive testing methods.

PTI’s VeriPac 465, the latest addition to the vacuum decay series is a robust and reliable solution for testing pharmaceutical containers and parenteral products, achieving highly sensitive sub-micron leak detection. The VeriPac 465 is the most sensitive vacuum based technology on the market to-date.

Benefits of Vacuum Decay Technology:

• Non-destructive, non-subjective, no sample preparation
• Deterministic test method that provides quantitative results
• Multiple package testing in a single test cycle
• Economical with rapid return on investment
• ASTM Test Method, FDA standard and USP 1207 Guidance

2. Microcurrent HVLD technology: Microcurrent HVLD is a unique High Voltage Leak Detection technology, highly effective across all liquid filled parenteral products. Its applications include liquid-based products ranging from extremely low conductivity sterile water for injection (WFI) to large molecule-based proteinaceous products with suspensions. Its ability to detect small pinholes, micro cracks and seal defects makes it an ideal choice for testing high risk pharmaceutical and parenteral products.

Benefits of PTI’s MicroCurrent HVLD technology:

• Non-destructive, non-invasive, no sample preparation
• Highly effective across all parenteral products, including extremely low conductivity liquids (WFI)
• Ensure higher levels of accuracy and reliability in test results
• Simplifies the inspection and validation process
• Offline and 100% online inspection
• Referenced in USP 1207 Guidelines

Often described as the driving force of pharmaceutical industry, biologic drugs have the ability to address chronic diseases, unmet medical needs and comprise of more than half of the drugs in development. These are generally large complex molecules, derived from human, animal, or microorganisms through biotechnology. Examples include blood components, cells, vaccines, tissues, and recombinant proteins. The ability of biological drugs to treat life threatening diseases coupled with aging population has lead to tremendous growth in the global biological drugs market. However, the rapid growth of biological products has also increased packaging challenges to deliver safe and effective products.

Drug contamination is a serious concern in any medical industry; however, for biologics, it amplifies several folds because they are used to treat serious illnesses and chronic conditions. Contamination has a direct impact on product stability resulting in reduced shelf life and efficacy. Along with maintaining an acceptable shelf-life, there are other challenges too. Another important factor that can affect the quality of a drug is environmental conditions. For example, if a product is exposed to extreme temperature during transit, the product quality may be compromised. A biologic can also lose its stability if it’s unable to withstand variations in light and chemicals that it might encounter. Therefore, in order to cover packaging challenges associated with biological products, ensuring its container closure integrity is crucial.

Ensuring package integrity with PTI’s MicroCurrent HVLD technology

PTI’s MicroCurrent HVLD technology is a non-destructive, non-invasive container closure integrity test (CCIT) method that is found to be highly effective across applications such as pre-filled syringes, vials, cartridges, ampoules, BFS, bottles and pouches. This technique can precisely detect any leak in a wide range of liquid-filled products including extremely low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. Under this method, the sealed container is scanned using electrode probes to detect the presence of any leak. Defects in the container as well as its approximate location can be identified by analyzing a change in the current flow. MicroCurrent HVLD technology utilizes about 50% less voltage and exposes the product and environment to less than 5% of the voltage when compared to conventional HVLD solutions. It is one of the most effective CCI technologies for all parenteral and biologic products.

Benefits of PTI’s MicroCurrent HVLD technology

• Non-destructive, non-invasive, no sample preparation
• Highly effective across all parenteral products, including extremely low conductivity liquids (WFI)
• Ensure higher levels of accuracy and reliability in results
• Offline and 100% online inspection at high production speeds
• Simplifies the inspection and validation process
• Referenced in USP 1207 Guideline

Seal integrity plays a vital role in ensuring the quality of packaging products. Even a minute defect in the seal can initiate a leak, which can compromise the quality of the product and directly affect its shelf life. It can also result in huge financial losses to the manufacturer. That being said, manufacturers give considerable importance to conducting appropriate seal integrity tests to ensure package integrity at every stage of its lifecycle.

Seal integrity testing methods can be classified into two- Destructive testing methods and Non-Destructive testing methods. Since under Destructive methods, the packages may get destroyed, its popularity has steadily declined over the past few decades due to this waste and high cost. “There is a huge shift in the industry towards deterministic and quantitative test methods,” says Oliver Stauffer, Chief Executive Officer at PTI - Packaging Technologies & Inspection. “This includes vacuum decay and airborne ultrasound for medical device applications. The industry is currently moving away from dye ingress and manual visual inspection because there are so many blind spots in applying them and there’s a huge false sense of assurance.”

Seal quality inspection techniques offered by PTI:

Vacuum Decay technology is a non-destructive Container Closure Integrity test (CCIT) method, used for seal quality inspection in nonporous, rigid or flexible packages. With the ability to detect leaks down to the sub-micron level, , Vacuum Decay technology is identified as one of the most practical vacuum-based leak detection methods. Its ability to provide quantitative, reliable and repetitive test results make it ideal solution for seal quality inspection in Pharmaceutical, Medical Device and Food and Nutrition industries.

Under this method, the sample packages are first placed in a close fitting evacuation test chamber that contains an external vacuum source. The vacuum levels and changes in vacuum over a pre-determined time are closely monitored. The single or dual vacuum transducer technology is used to monitor the test chamber for both the level of vacuum as well as the change in vacuum over a predetermined test time. The changes in the absolute and differential vacuum indicate the presence of leaks and defects within the package.Over the past few years, Vacuum Decay technology has seen great advancements in the form of PTI’s PERMA-VAC technology and VeriPac FLEX Series.

The next generation PERMA-VAC technology is a single or dual vacuum transducer technology that has made the VeriPac line of test systems the most sensitive vacuum-based leak tests available in the market. It has higher test sensitivity for providing accurate and reliable results and can be applied to rigid and semi-flexible packages alike. PTI’s PERMA-VAC technology ensures the most stable test measurement ever achieved through vacuum decay.

VeriPac FLEX series is an ideal package inspection solution for dry filled pouches and flexible packaging. To accommodate different package formats and test sensitivity requirements, VeriPac FLEX series is available in several configurations with multiple test chamber sizes.

 

2.Airborne Ultrasound technology:

Airborne Ultrasound technology is yet another seal quality inspection technique, which is capable of non-destructively conducting advanced seal quality inspection of pouches and flexible packaging. It is capable of accommodating multiple packaging materials like Tyvek, paper, foil, film, aluminum, plastic and poly and is also proven to provide deterministic, reliable and accurate test results.

As the name suggests, this method utilizes ultrasound waves to detect defects in package seals. Ultrasound waves are passed through the material as the package seal moves along the sensor head. This causes reflections of sound waves. Such signal strength variations are closely monitored to identify defects if any. Its ability to evaluate seal quality even under conditions where the defect may not result in a leak, makes Airborne Ultrasound technology a practical choice for seal quality inspection across different industries.

PTI’s Seal-Scan (Offline) and Seal-Sensor (Online) are the latest advancements to the ultrasound test series. Both these technologies make use of non-contact airborne ultrasonic testing technology and have been established as one of the most effective methods for inspection of flexible package seals. Airborne ultrasound is also an ASTM Test Method F3004 for seal quality inspection.

 

Ensuring pharmaceutical package integrity has always been a priority for drug product manufacturers. However, over the past few decades, innovations in health care sector have also accelerated pharmaceutical package integrity challenges. Although testing package quality of all healthcare products is important, in the case of parenteral products it is amplified significantly. Parenteral products are defined as injectible products that can be either liquid or powders. Solutions can contain suspensions, emulsions and be proteinaceous in nature. ”. Since these drugs are directly administered into human bodies, ensuring complete integrity of such packages is crucial. Common packaging formats for parenteral products include Liquid-filled containers such as vials, ampoules, syringes, BFS and auto injectors; Lypholized (powder) products are often packaged in vials. Even a minute breach in the package can cause microbial contamination leading to product deterioration. Hence ensuring container closure integrity is a critical process in the life cycle of parenteral products.

What is HVLD Methodology?

High Voltage Leak Detection (HVLD)) is a non-destructive Container Closure Integrity Test (CCIT) method used primarily to evaluate closure integrity of parenteral product packaging. HVLD technology makes use of quantitative electrical conductivity measurement principles. This method operates by passing high voltage micro current signals through sample packages. Under the presence of a leak, the electrical resistance of the sample declines, causing an increase in current. Applications of High Voltage Leak Detection Technology include testing of the following package formats:

• Pre-filled Syringes
• Ampoules
• Drug Product Cartridges
• Liquid Filled Vials
• Blow-Fill-Seal (BFS) Container

PTI’S MicroCurrent HVLD technology has revolutionized the conventional HVLD method. MicroCurrent HVLD is a non-destructive, non-invasive CCI technique that can be applied to a wide range of liquid filled products including low conductivity sterile water for injection (WFI) and highly proteinaceous drug products within suspensions. PTI’s E-scan HVLD, a highly sensitive CCI testing process uses electrode probes to scan sealed non-conductive containers. Under the presence of a leak, there will be a change in current flow indicating a defect in the container along with its approximate location. This unique technique uses about 50% less voltage and exposes the product and environment to less than 5% of the voltage. An important feature of E-scan HVLD is its ability to easily shift from the laboratory offline to 100% inline testing applications. With the capability to accommodate multiple packaging formats including glass, plastic or poly laminates, it is an ideal solution for parenteral package testing.

Benefits of MicroCurrent HVLD:

• Deterministic, non-destructive, non-invasive
• High level of repeatability and accuracy
• Ideal package integrity solution for parenteral products
• Low voltage exposure to the product and environment
• Offline and 100% online inspection at high production speeds

Today’s healthcare industry assures treatments that were unimaginable a few years ago. As pharmaceutical industry grows in importance, the techniques of primary packaging for healthcare products, especially parenteral products has taken on new prominence. Common parenteral packaging methods include Liquid-filled containers such as vials, ampoules, syringes, blow-fill-seals and auto-injectors and containers filled with lyophilized products. Since these drugs are directly administered into human bodies, high sensitivity integrity tests are required to ensure product quality throughout its shelf life. For reasons of safety, packaging material, integrity and design are regulated by Food And Drug Administration as strictly as the product itself.

Container Closure Integrity Testing is a leak detection test conducted using a non-destructive packaging inspection system to protect the drug from any possible contamination. It is a crucial step in evaluating safety and integrity of the primary packaging so as to maintain a sterile barrier and to avoid leakage resulting in contamination of the drug. Packaging components like bottles, vials, syringes that are in direct contact with the product are called primary components while aluminum caps, cardboard boxes are secondary components as they are not in direct contact with the product. Proper packaging should be a priority for all drug products, but in case of parenteral products, these concerns amplifies several folds as they are directly injected. Hence initiating a proper container closure system is vital for product and consumer safety.

Although Container Closure Integrity Testing(CCIT) can be performed in many different ways, it can be broadly classified into Probabilistic methods and Deterministic methods. Probabilistic test methods including Microbial Challenge by Immersion, Tracer Liquid Tests (e.g. Dye Ingress), Bubble Tests etc. are traditional test methods where result accuracy may be uncertain. On the other hand, Deterministic test methods like Electrical Conductivity and Capacitance Test (HVLD), Laser-based Gas Headspace Analysis, Mass Extraction, Pressure Decay provide quantitative results with high accuracy. The United States pharmacopeia released guidance in 2016 stating that deterministic methods are preferred over probabilistic test methods.Packaging Technologies And Inspection (PTI’s) Microcurrent HVLD technology and vacuum decay technology are the latest inventions in package integrity testing of parenteral products.

1. Microcurrent HVLD Technology: Microcurrent HVLD is a unique High Voltage Leak Detection Technology, highly effective across all parenteral products. Its Applications include liquid-based products ranging from extremely low conductivity sterile water for injection (WFI) to proteinaceous products with suspensions. Its ability to detect small pinholes, micro cracks and seal defect detection down to single-digit microns makes it an ideal choice for testing parenteral products.

2. VeriPac Vacuum Decay Technology: VeriPac Vacuum Decay Technology, based on the ASTM vacuum decay leak test method (F2338-09) and accredited by the FDA for package integrity testing, is a non-destructive inspection system, capable of defect detection down to 0.002 cc/min. This system is applicable for empty and pre-filled syringes, liquid-filled and lyophilized vials and other flexible and rigid liquid-filled packaging. Depending on the package type and leak test sensitivity needed, appropriate VeriPac model can be selected.

PTI’s next generation PERMA- VAC technology addresses vacuum decay detection at the very core of physical test measurement by controlling the test system volume and maximizing the SNR between good and defective samples. This makes PERMA-VAC the most reliable vacuum-based leak test available in the market.

The global pharmaceutical industry has seen tremendous growth over the last few decades. The complex nature of the industry coupled with frequent breakthroughs has made it a favorite subject of scrutiny. Since any defect in the packaging of drugs can have serious consequences, assuring the quality of the packaging is of prime interest for every manufacturer. Pharmaceutical products are expected to be free from microbial contamination and safe to use right from production throughout their shelf-life. The drug’s stability can be adversely affected through contamination in the form of oxygen, humidity or microbiological ingress. In order to prevent such risks, integrity tests with high sensitivity are required.

Previously, only sterility testing was conducted on pharmaceutical packaging. However, when it was realized that sterility testing alone is not sufficient to hold the integrity of the medical products, the US FDA published Guidance for Industry for Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products. This emphasised the importance of verification of microbial barrier properties of a pharmaceutical product package (i.e., CCI). FDA defines Container Closure Integrity Testing (CCIT) “as the sum of packaging components that together contain and protect the dosage form”.

Container Closure Integrity Testing is a method of leak detection using a non-destructive packaging inspection system to prevent possible contamination. Such a test is essential since any defect in the container can cause external particles to enter the product, thereby reducing its shelf life. Implementing right Container Closure System has been of prime importance for a manufacturer as it affects both the product and the patient. Hence, the relevance of CCI Testing in the pharmaceutical industry has steadily increased over the years. Contaminants that can enter a product include micro-organisms, reactive gases, and other substances. CCIT ensures product quality is maintained from the point of manufacture throughout its distribution and use. Container closure systems include primary packaging components and secondary packaging components. Components such as a glass vial or syringe, which come into direct contact with the product, are primary packaging components. On the other hand, components that are crucial to ensure correct package assembly, such as aluminum caps, over stoppers etc. are the secondary packaging components

CCI Testing Methods

Container closure integrity testing can be performed in many different ways. Each method has its own merits and demerits. A number of factors have to be considered while selecting appropriate testing methods. These factors include, but are not limited to; the reliability of the test method, material of the primary package and inline versus an offline testing requirement. CCI testing methods can also be selected depending on specific desired outcomes. Examples of desired outcome include: identifying the presence of leak paths, understanding leak path’s location, evaluating leak rate for the whole package, and measuring potential for microbial ingress. The United States pharmacopeia released guidance in 2016 stating that deterministic methods are preferred over probabilistic test method.

1. Probabilistic methods: Here, the testing methods are more traditional, and the accuracy of the result is uncertain. The probabilistic methods include the following:

• Microbial Challenge by Immersion
• Tracer Liquid Tests (e.g. Dye Ingress)
• Bubble Tests
• Tracer Gas (Sniffer Mode)

2. Deterministic methods: Such methods provide quantitative results with a higher level of accuracy. The chances of errors are also minimal. The deterministic methods include the following:

• Electrical Conductivity and Capacitance Test (HVLD)
• Laser-based Gas Headspace Analysis
• Mass Extraction
• Pressure Decay
• Tracer Gas (vacuum mode)
• Vacuum Decay